5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
| Autor: | Esteban Ribera, Warren, Margaret Johnson, Adriano Lazzarin, SS Chen, L Weitner |
|---|---|
| Předmět: |
medicine.medical_specialty
Efavirenz business.industry Public Health Environmental and Occupational Health Lamivudine Pharmacology medicine.disease Emtricitabine Discontinuation Zidovudine Regimen chemistry.chemical_compound Infectious Diseases Acquired immunodeficiency syndrome (AIDS) Tolerability chemistry Internal medicine Poster Presentation medicine business medicine.drug |
| Zdroj: | Europe PubMed Central Journal of the International AIDS Society |
| ISSN: | 1758-2652 |
| Popis: | The goal of highly active antiretroviral therapy (HAART) is to suppress HIV RNA to undetectable levels over many years and is primarily dependent on adherence, which is aided by using a once daily regimen with good tolerability and low pill burden. In Study 934 the time to discontinuation for the twice daily regimen of EFV qd + zidovudine/lamivudine bid was significantly shorter than for the once daily regimen (EFV+FTC+TDF) (p=0.003). Herein are the 5 year safety and efficacy data for this once daily regimen. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P6 Cite this article as: Lazzarin et al.: 5-year safety and efficacy of the oncedaily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF). Journal of the International AIDS Society 2010 13(Suppl 4):P6. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113064/ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|